Clinical trials: Flu
Influenza
Safety and Immunogenicity of A/H1N1v Vaccines in Healthy Adults
The purpose of this study is to evaluate the antibody response to one and two doses of influenza A/H1N1v vaccine in healthy adults.
- Trial name
- NCT00943358
- Testing
- MF59 H1N1 vaccine, Plain H1N1 vaccine
- Where
- United Kingdom
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- University Hospitals, Leicester
Influenza
Half-Dose Flu Vaccine Study in Healthy Adults
It appears likely that there will be a delay and possibly a reduction in the amount of influenza vaccine available for the 2000-2001 influenza season.
- Trial name
- NCT00006146
- Testing
- Approved influenza virus vaccine.
- Where
- 6 sites in United States
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza Vaccination
Family Physician Nudges for Influenza Vaccination Among Older Adults
The goal of this clinical trial is to learn if a family-physician nudge intervention works to improve influenza vaccination among adults aged 65 years and older in China.
- Trial name
- NCT07864597
- Testing
- Family Physician Influenza Vaccination Nudge
- Volunteers
- 3,060 people, healthy volunteers welcome
- Sponsor
- Fudan University
Influenza, Human
The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)
The purpose of this study is to evaluate the safety, tolerance, and immunogenicity of MAS-1-Adjuvanted seasonal inactivated influenza vaccine (IIV) (MER4101) with hemagglutinin dose escalation compared to non-adjuvanted…
- Trial name
- MER4101 (NCT02500680)
- Testing
- MER4101, Inactivated Influenza Vaccine
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Nova Immunotherapeutics Limited
Influenza, Human
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age
This Phase 2, randomized, observer-blind, dose-confirmation clinical study evaluated different formulations of MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine.
- Trial name
- NCT05501561
- Testing
- Experimental: IIV-A Investigational IIV-A administered as a single dose intramuscularly on Day 1, Experimental: aIIV-B Investigational aIIV-B administered as a single dose intramuscularly on Day 1, Experimental: aIIV-C Investigational aIIV-C administered as a single dose intramuscularly on Day 1
- Where
- 47 sites in United States
- Volunteers
- 1,056 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 09/10 Season
Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year.
- Trial name
- NCT00881842
- Testing
- Trivalent influenza subunit vaccine Influvac
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Abbott Biologicals
Influenza
Safety and Pharmacokinetics Study of Human Monoclonal Antibody (FGI-101-1A6)
The purpose of this study is to determine the safety and tolerability of the anti-TSG101 human monoclonal antibody (FGI-101-1A6)when administered intravenously to healthy volunteers.
- Trial name
- NCT01299142
- Testing
- FGI-101-1A6
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Functional Genetics Inc.
Smoking
Effects of Sulforaphane (SFN) on Immune Response to Live Attenuated Influenza Virus in Smokers and Nonsmokers
Vegetables such as broccoli, cauliflower, kale and cabbage are particularly rich in a plant chemical called sulforaphane (SFN) which boosts production of certain "defense" enzymes that increase the activity of antioxidants.
- Trial name
- NCT01269723
- Testing
- Broccoli sprout homogenate, Alfalfa sprout homogenate
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Influenza, Human
Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines
This study will evaluate the efficacy, safety and immunogenicity of one or two 0.25 mL or 0.5 mL intramuscular injections of an adjuvanted influenza vaccine compared with non-influenza and non-adjuvanted influenza control…
- Trial name
- NCT00644059
- Testing
- Adjuvanted trivalent inactivated subunit influenza vaccine, Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine, Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine
- Where
- 101 sites in Finland, Germany and 1 more
- Volunteers
- 4,902 people, healthy volunteers welcome
- Sponsor
- Novartis
Seasonal Influenza
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
The primary objectives of this study are to evaluate the humoral immunogenicity of mRNA-1010 relative to that of an active comparator against vaccine-matched influenza A and B strains at Day 29, and to evaluate the safety and…
- Trial name
- NCT05415462
- Testing
- mRNA-1010, Fluarix Tetra
- Where
- 53 sites in Argentina, Australia and 3 more
- Volunteers
- 6,102 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Coverage Rate of Vaccination for Influenza
Realization of the Recommendation for Influenza Vaccination in Pregnant Women
Introduction: In 2010, the vaccination recommendations for pregnant women against seasonal influenza were published by the German Standing Committee on Vaccination (STIKO).
- Trial name
- NCT03007797
- Testing
- vaccination rate for influenza
- Volunteers
- 236 people, healthy volunteers welcome
- Sponsor
- University Hospital, Saarland
Influenza
Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Healthy Subjects Aged Over 6 Months Old to 18 Years Old
This is an open study of the use of AdimFlu-S (2010-2011 season) vaccine in young subjects aged between 6 months old to 18 years old. All participants will be divided into three age cohorts.
- Trial name
- NCT01356342
- Testing
- AdimFlu-S 2010-2011, inactivated
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Asthma in Children, Vaccine Adverse Reaction
Safety of LAIV4 in Children With Asthma
This is a prospective randomized, open label clinical trial in approximately 300 children aged 5-11 years with a physician diagnosis of persistent asthma.
- Conditions
- Asthma in Children, Vaccine Adverse Reaction, Vaccine Reaction, Asthma
- Trial name
- NCT03600428
- Testing
- Live Attenuated Influenza Vaccine (LAIV), Inactivated Influenza Vaccine (IIV)
- Where
- 3 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Influenza (Healthy Volunteers)
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older
Primary Objective: Immunogenicity: To describe the immune response induced by high-dose quadrivalent influenza vaccine (QIV-HD) and AdimFlu-S (QIS) by hemagglutinin inhibition (HAI) measurement method in all participants.
- Trial name
- NCT04537234
- Testing
- High-Dose Quadrivalent Influenza Vaccine, Standard-Dose Quadrivalent Influenza Vaccine
- Where
- 4 sites in Taiwan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Routes of Immunization and Flu Immune Responses
The project aims to evaluate the impact of skin routes of immunization (transcutaneous and intradermal vs intramuscular) on cellular and humoral responses to seasonal influenza vaccination in adults (18-45 years old).
- Trial name
- FLUWAY (NCT01707602)
- Testing
- INTANZA® 15, Vaxigrip®, INTANZA® 15 T
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Seasonal Influenza
A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults
The study comprises 3 parts: Phase 1/2, Phase 2 Northern Hemisphere (NH), and Phase 2 extension. The primary objective of this study is to evaluate the safety, reactogenicity, and humoral immunogenicity of mRNA-1010 vaccine.
- Trial name
- NCT04956575
- Testing
- mRNA-1010, Active Comparator
- Where
- 21 sites in United States
- Volunteers
- 885 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza, Human
Burden of Influenza at Emergency Department (ED) Level in European Countries
This study plans to conduct enhanced influenza surveillance at a hospital emergency department level independent of underlying influenza-like symptoms.
- Trial name
- NCT04244500
- Testing
- swab sampling
- Where
- Germany
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- University of Rostock
Influenza
A Clinical Trial With Influenza A/H1N1 Vaccines
A single center, stratified, randomized and double-blind phase IV clinical trial is to be conducted in healthy elders (equal to or more than 61 years), adults (18-60 years), adolescents (12-17 years) and children (3-11 years) to…
- Trial name
- NCT00956111
- Testing
- split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose, split-virion, adjuvanted H1N1 vaccine of 15 μg per dose, split-virion, non-adjuvanted H1N1 vaccine of 15 μg per dose
- Where
- China
- Volunteers
- 1,614 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Antioxidative Stress, Cold
Taxifolin/Ergothioneine and Immune Biomarkers in Healthy Volunteers (TaxEr)
The complexities of the immune system make measuring the impact of dietary interventions upon its function challenging. The immune system is highly responsive to environmental influences, including the diet.
- Conditions
- Antioxidative Stress, Cold, Influenza, Aging
- Trial name
- TaxEr (NCT05190432)
- Testing
- Taxifolin, Ergothioneine, Control
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Southampton
Influenza, Influenza Immunisation
Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine
This is a Phase II randomized, double-blind, placebo-controlled trial in 120 males and non-pregnant females, 18 to 49 years old, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03058692
- Testing
- Influenza Multimeric-001 Vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine
- Where
- 3 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.